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PreviewsHGF co-localization with the endothelial
marker CD31 and the dendritic cell
marker CD11c by microscopy. It is
possible that dendritic cells take up HGF
and travel from the myocardium to lymph
nodes, but this was not formally tested.
The authors argue that T cells interacting
with HGF in lymph nodes will be primed
for a cardiotropic chemokine-receptor
signature during simultaneous antigen
presentationandco-stimulation (Figure1).
It is indeed plausible that expression
of cardiotropic chemokine receptors
might guide T cells into the heart. How-
ever, what is the role of enhanced chemo-
kine secretion by T cells in response to
HGF? Is this an autocrine loop that keeps
primed T cells in the lymph node for some
time or do HGF-treated cells exhaust
after prolonged HGF treatment and stop
chemokine secretion? The authors did
not test different durations of HGF stimu-
lation followed by an absence of HGF to
clarify this. Thus, it is possible that HGF
deposition in the injured myocardium
might induce the relevant chemokines
that serve as direct homing signals. In
the latter case, increased chemokine
and chemokine receptor expression by
T cells themselves would help to retain
T cells in the myocardium. Indeed, some
observations support the idea that fulldifferentiation into functional T effector/
memory cells might require antigen pre-
sentation and second activation in non-
lymphoid tissue (Ley, 2014). HGF might
be a co-factor required for such tissue-
specific activation and retention in the
heart.
Beyond the findings presented in the
current study, some remaining questions
will have to be answered in the future.
First, this study required anti-CD3 and
anti-CD28 stimulation to exert HGF’s acti-
vating effects on T cells, which raises the
question whether weaker TCR-signaling
events, as would be expected from natu-
ral antigen stimulation by APCs, would
induce the same cardiotropic signatures
in vivo. Second, the authors find that be-
sides CCR5, both CCR4 and CXCR3 are
required for T cell homing. This is unex-
pected, because T helper (Th) cell lineage
commitment typically results in modified
chemokine receptor expression, defining
CXCR3 as landmark of Th1 and CCR4
of Th2 cell polarization (Sallusto et al.,
1998).
Taken together, the results presented
by Komarowska et al. (2015) introduce a
new paradigm for cardiac T cell tropism.
In addition, the data are exciting because
they raise the potential to alter tissue-
tropism of T cells that might modulateImmunityT cell-mediated pathology in the heart—
and relevant therapeutic compounds are
already available.REFERENCES
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Atherosclerosis is a lipid-storage disease of arteries that is exacerbated by chronic inflammatory processes.
In this issue of Immunity, Hu et al. (2015) demonstrate that T cell responses in atherosclerotic lesions are
controlled in tertiary lymphoid organs in the arterial wall.Atherosclerosis is a multifactorial cardio-
vascular disease that is characterized by
elevated lipid amounts in the blood and
deposition of lipids in and subsequent
chronic inflammation of the arterial wall.
The immune system already detects smallchanges in the integrity of the blood
vessel wall and reacts with macrophage
and T cell infiltration into early sub-
endothelial ‘‘fatty streaks’’ (Hansson and
Hermansson, 2011). With progressive
deposition of low-density cholesteroland formation of cholesterol crystals,
more immune cells infiltrate the vascular
lesion, leading to enhanced production
of collagens and fibrotic remodeling
of the atherosclerotic plaque. Uncon-
trolled growth and destabilization of42, June 16, 2015 ª2015 Elsevier Inc. 981
Figure 1. Vascular Smooth Muscle Cells Drive Arterial Tertiary Lymphoid Organ
Development in Atherosclerosis in Apolipoprotein-E-Deficient Animals
Activation of LTbR-competent VSMCs is required for the development of ATLOs adjacent to atheroscle-
rotic plaques in the arterial wall (left panel). ATLOs contain defined B cell follicles (BF) and T cell zones (TZ)
where naive T cells are educated by antigen-presenting cells, such as macrophages and dendritic cells.
Naive T cells are activated and converted into induced T regulatory cells, which might influence anti-in-
flammatory macrophages and thereby ameliorate plaque formation. In the presence of ATLOs, formation
of atherosclerotic plaques is limited (left panel). Selective ablation of the LTbR in VSMC of apolipoprotein-
E-deficient animals prevents ATLO development. As a consequence, aging mice show exacerbated
development of atherosclerotic lesions (right panel).
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Previewsthe plaque leads to narrowing of the
arterial lumen (stenosis) and might
precipitate plaque rupture with life-threat-
ening ischemic infarctions in brain and
heart (Hansson, 2005). Strikingly, it has
remained enigmatic whether, where,
and how the chronic inflammatory pro-
cesses in atherosclerotic arteries are
controlled.
Immune reactivity is, to a large extent,
determined through the interaction of
different immune cells within secondary
lymphoid organs (SLOs) such as lymph
nodes and spleen (Junt et al., 2008). How-
ever, during chronic inflammatory condi-
tions, such as autoimmune diseases or
persistent infection, tertiary lymphoid or-
gans (TLOs) can develop. TLOs exhibit
structural segregation of T and B cell
zones, but lack, unlike proper SLOs, a
capsule and clearly defined antigen-sam-
pling zones such as the subcapsular sinus
of lymph nodes. Earlier observations by
Wick and colleagues have suggested
that atherosclerotic lesions in humans
harbor lymphoid tissue-like structures982 Immunity 42, June 16, 2015 ª2015 Elsev(Wick et al., 1997). Indeed, arterial TLOs
(ATLOs) develop within the lamina adven-
titia of large and medium sized arteries,
display distinct compartmental organiza-
tion with T cell zone and B cell follicles
(Watanabe et al., 2007) and provide inter-
action space for effector and memory
T cells with macrophages and dendritic
cells in proximity to atherosclerotic le-
sions (Hansson and Hermansson, 2011).
In a previous study, Habenicht and col-
leagues have shown that ATLOs foster
access of T cells to atherosclerotic areas
through formation of high endothelial
venules (HEVs) and that growth andmatu-
ration of ATLOs in advanced atheroscle-
rosis of apolipoprotein E-deficient mice
correlate with disease severity (Gra¨bner
et al., 2009).
The present study of this group
(Hu et al., 2015) reveals that a forceful
immunological control reaction underlies
the connection between atherosclerotic
lesion development and ATLO formation.
In other words, ATLOs associated with
chronic atherosclerotic lesions are theier Inc.source of anti-atherogenic immune cells
(Figure 1). The intriguing findings of this
paper include the demonstration that
ATLOs are not only homing sites for
memory T cells, but that these structures
are capable to attract and retain naive
CD4+ and CD8+ T cells. Egress of naive
T cells in the proximity of atherosclerotic
lesions was regulated by sphingosine-1-
phosphate receptor 1 (S1PR1), hence
following the same rules as retention of
naive T cells in lymph nodes. Moreover,
adoptive transfer experiments and two-
photon microscopy revealed that ATLO
and lymph node T cells exhibit almost
identical motility and migration patterns.
The presence of professional antigen-
presenting cells (APCs) including mono-
cyte-derived and conventional DCs in
ATLOs is interpreted as evidence for a
contribution of these APCs in T cell acti-
vation. While such direct APC-T cell
interaction within ATLOs remains to be
demonstrated, the data show that the
retention of T cells in this environment
was critical for local differentiation of
naive T cells into FoxP3+CD25+ regulatory
T cells (Figure 1). Thus, this study shows
that ATLOs support local induction of a
primary T cell response including the
generation of those T cells that attenuate
immune responsiveness. Moreover, the
study suggests that there is an intricate
connection between ATLO development
and control of anti-atherosclerotic im-
mune responses.
TLO formation follows, in principle, the
general rules that govern the develop-
ment of SLOs. The constitutive chemo-
kine receptors CXCR5 and CCR7 and
the lymphotoxin-b receptor (LTbR) are
central molecular players in the devel-
opment of SLOs (van de Pavert and Me-
bius, 2010). The ignition for lymphoid
organogenesis requires the presence of
LTa1b2-expressing hematopoietic lym-
phoid tissue inducer (LTi) cells that trigger
non-hematopoietic lymphoid tissue orga-
nizer (LTo) cells. It has been suggested
that medial vascular smooth muscle cells
(mVSMCs) can function as LTo cells dur-
ing ATLO formation, provided that suffi-
cient lympho-organogenic signals are
generated by immune cells that aggre-
gate beneath atherosclerotic lesions (Lo¨t-
zer et al., 2010). Indeed, mVSMCs in the
aortic adventitia of aged apolipoprotein
E-deficient mice produce the constitu-
tive chemokines CXCL13 and CCL21 in
Immunity
Previewsa LTbR-dependent fashion. Moreover,
stimulated mVSMCs form a fibroblastic
reticular cell network-like structure that
is typical for SLOs (Gra¨bner et al., 2009).
However, the LTo cell function is not
confined to fibroblastic cells because
lymph node formation, for example, re-
quires LTbR signaling in vascular endo-
thelial cells (Onder et al., 2013). Hu et al.
(2015) solved not only the question con-
cerning the nature of the organizer cell
for ATLO formation, but also found an
elegant way around the confounding
factor that altered immune responsive-
ness in globally LTbR-deficient mice led
to accelerated atherosclerosis. In the
core dataset of this study, conditional
Ltbr gene ablation specifically in VSMC
has been achieved through SM22a pro-
moter-driven Cre recombinase expres-
sion. Thorough characterization of SLOs
of conditionally LTbR-deficient animals
on the apolipoprotein E-deficient back-
ground revealed the absence of general
immune system alterations. Importantly,
selective ablation of the LTbR revealed
that VSMCs limit atherosclerotic dis-
ease progression in aging apolipoprotein
E-deficient mice, while initial lesion devel-
opment was not affected. Hence, these
findings suggest that the senescent im-
mune system selectively employs the
LTbR on VSMCs to foster ATLO formationand thereby locally restrains the athero-
sclerotic process. However, it needs to
be clarified in future studies how T cell
education within ATLOs impinges on the
chronic atherosclerotic lesion develop-
ment. It is possible that ATLO-dependent
local induction of regulatory T cells fosters
generation of anti-inflammatory macro-
phages and antagonizes foam cell forma-
tion (Figure 1).
The findings of Hu et al. (2015) provide
not only novel insight into core processes
during atherogenesis, but also teach a
new lesson on the role of TLOs in the pro-
gression of local inflammation. In fact, it
has been a matter of debate whether
TLOs enforce or attenuate chronic inflam-
mation or autoimmune disease. One ma-
jor obstacle in resolving this issue has
been the genetic link between SLO devel-
opment and TLO formation. Hence,
uncoupling of TLO formation from SLO
development through VSMC-specific ge-
netic Ltbr-ablation clearly points toward
a novel and important immune regulatory
function of TLOs. Identification of specific
markers for LTo cells in TLOs of other
tissues would open new options for ge-
netic manipulation of these cells in vivo
and to revisit their role in chronic inflam-
matory reactions.
In sum, TLOs in the wall of atheroscle-
rotic arteries might guide us to new break-Immunitythroughs in getting control on chronic
inflammation.
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In this issue of Immunity, Conde et al. (2015) showed that a costimulatory blockade favors the accumulation
of CD209a+ macrophages which, upon interaction with fucosylated tissue ligands, promotes the expansion
of CD4+Foxp3+ Treg cell number.The control of peripheral tolerance to self-
antigens is one of the mechanisms that
define immune homeostasis. An effective
peripheral tolerance ensures that autor-
eactive T cells that have escaped nega-tive selection during thymic education
are kept under control to avoid autoimmu-
nity. In addition, excess of tolerance is
avoided to allow the immune system to
respond with proper capacity againstpathogens. Dysregulation of this fine
equilibrium leads to important repercus-
sions on both sides of the balance: the
development of autoimmunity when toler-
ance is poor and the facilitation of tumor42, June 16, 2015 ª2015 Elsevier Inc. 983
